Open access · OA
via OpenAlex
Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways Delays Axonal Degeneration after Axotomy
Yo Sasaki, Toshiyuki Araki, Jeffrey Milbrandt
Journal of Neuroscience · 2006 · ▲ 272 citations
Abstract
Axonal degeneration occurs in many neurodegenerative diseases and after traumatic injury and is a self-destructive program independent from programmed cell death. Previous studies demonstrated that overexpression of nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1) or exogenous application of nicotinamide adenine dinucleotide (NAD) can protect axons of cultured dorsal root ganglion (DRG) neurons from degeneration caused by mechanical or neurotoxic injury. In mammalian cells, NAD can be synthesized from multiple precursors, including tryptophan, nicotinic acid, nicotinamide, and nicotinamide riboside (NmR), via multiple enzymatic steps. To determine whether other components of these NAD biosynthetic pathways are capable of delaying axonal degeneration, we overexpressed each of the enzymes involved in each pathway and/or exogenously administered their respective substrates in DRG cultures and assessed their capacity to protect axons after axotomy. Among the enzymes tested, Nmnat1 had the strongest protective effects, whereas nicotinamide phosphoribosyl transferase and nicotinic acid phosphoribosyl transferase showed moderate protective activity in the presence of their substrates. Strong axonal protection was also provided by Nmnat3, which is predominantly located in mitochondria, and an Nmnat1 mutant localized to the cytoplasm, indicating that the subcellular location of NAD production is not crucial for protective activity. In addition, we showed that exogenous application of the NAD precursors that are the substrates of these enzymes, including nicotinic acid mononucleotide, nicotinamide mononucleotide, and NmR, can also delay axonal degeneration. These results indicate that stimulation of NAD biosynthetic pathways via a variety of interventions may be useful in preventing or delaying axonal degeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1523/jneurosci.2320-06.2006
- Canonical
- link ↗
- Fetched
- 2026-06-16 MST
Cite this
APA
Sasaki, Y., Araki, T., & Milbrandt, J. (2006). Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways Delays Axonal Degeneration after Axotomy. <em>Journal of Neuroscience</em>. https://doi.org/10.1523/jneurosci.2320-06.2006
Vancouver
Sasaki Y, Araki T, Milbrandt J. Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways Delays Axonal Degeneration after Axotomy. Journal of Neuroscience. 2006. doi:10.1523/jneurosci.2320-06.2006.
BibTeX
@article{yo2006Stimul,
title = {Stimulation of Nicotinamide Adenine Dinucleotide Biosynthetic Pathways Delays Axonal Degeneration after Axotomy},
author = {Yo Sasaki and Toshiyuki Araki and Jeffrey Milbrandt},
journal = {Journal of Neuroscience},
year = {2006},
doi = {10.1523/jneurosci.2320-06.2006},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Journal of Clinical Endocrinology & Metabolism 2021
Open access · OA
Nicotinamide Riboside Enhances In Vitro Beta-adrenergic Brown Adipose Tissue Activity in Humans
Aging Medicine 2021
Open access · CC-BY
Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging
Biochemistry and Biophysics Reports 2024
Open access · CC-BY
Comparison of protective effects of nicotinamide mononucleotide and nicotinamide riboside on DNA damage induced by cisplatin in HeLa cells
The FASEB Journal 2021
Open access · OA
Reduced nicotinamide mononucleotide is a new and potent NAD <sup>+</sup> precursor in mammalian cells and mice
Molecular Metabolism 2019
Open access · CC-BY
A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor
Metabolites 2019
Open access · CC-BY